中国实验血液学杂志最新文献

{"title":"[Preparation and Evaluation of Clinical-Grade Human Umbilical Cord-Derived Mesenchymal Stem Cells with High Expression of Hematopoietic Supporting Factors].","authors":"Jie Tang, Pei-Lin Li, Xiao-Yu Zhang, Xiao-Tong Li, Fu-Hao Yu, Jia-Yi Tian, Run-Xiang Xu, Bo-Feng Yin, Li Ding, Heng Zhu","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.041","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.041","url":null,"abstract":"<p><strong>Objective: </strong>To prepare clinical-grade human umbilical cord-derived mesenchymal stem cells (hUC-MSC) with high expression of hematopoietic supporting factors and evaluate their stem cell characteristics.</p><p><strong>Methods: </strong>Fetal umbilical cord tissues were collected from healthy postpartum women during full-term cesarean section. Wharton's jelly was mechanically separated and hUC-MSCs were obtained by explant culture method and enzyme digestion method in an animal serum-free culture system with addition of human platelet lysate. The phenotypic characteristics of hUC-MSCs obtained by two methods were detected by flow cytometry. The differences in proliferation ability between the two groups of hUC-MSCs were identified through CCK-8 assay and colony forming unit-fibroblast (CFU-F) assay. The differences in multilineage differentiation potential between the two groups of hUC-MSCs were identified through induction of adipogenic, osteogenic, and chondrogenic differentiation. The mRNA expression levels of hematopoietic supporting factors such as <i>SCF, IL-3, CXCL12, VCAM1</i> and <i>ANGPT1</i> in the two groups of hUC-MSCs were identified by real-time fluorescence quantiative PCR(RT-qPCR).</p><p><strong>Results: </strong>The results of flow cytometry showed that hUC-MSCs obtained by the two methods both expressed high levels of CD73, CD90 and CD105, while lowly expressed CD31, CD45 and HLA-DR. The results of CCK-8 and CFU-F assay showed that the proliferation ability of hUC-MSCs obtained by explant culture method was better than those obtained by enzyme digestion method. The results of the triple lineage differentiation experiment showed that there was no significant difference in multilineage differentiation potential between the two grous of hUC-MSCs. The results of RT-qPCR showed that the mRNA expression levels of hematopoietic supporting factors <i>SCF, IL-3, CXCL12, VCAM1</i> and <i>ANGPT1</i> in hUC-MSCs obtained by explant cultrue method were higher than those obtained by enzyme digestion method.</p><p><strong>Conclusion: </strong>Clinical-grade hUC-MSCs with high expression levels of hematopoietic supporting factors were successfully cultured in an animal serum-free culture system.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"892-898"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress of Targeting BCL-2 and MCL-1 in Relapsed/Refractory Acute Myeloid Leukemia--Review].","authors":"Qian-Ying Ma, Zi-Xiu Wei, Juan Cheng","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.045","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.045","url":null,"abstract":"<p><p>Poor prognosis and high mortality rate are frequently observed in patients with relapsed/refractory acute myeloid leukemia (R/R AML), and there is no standard salvage therapy for these patients. As a method to evade apoptosis, cancer cells often upregulate anti-apoptotic proteins BCL-2 and MCL-1. Recently, venetoclax-based combination therapies have demonstrated promising prospects in treating R/R AML. However, the prevalent use of venetoclax comes with a new challenge of resistance. Upregulation of BCL-1 and/or MCL-1 is the main cause of venetoclax resistance and preemptively targeting BCL-2/BCL-XL/MCL-1 can be used to delay or forestall drug resistance. Thus, selective targeting of BCL-2 and MCL-1 is a viable treatment strategy. This review reports the latest clinical progress on targeting BCL-2 and MCL-1 in R/R AML.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"918-921"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Value of a Novel Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma].","authors":"Jie Zhao, Yan Jiang, Jia-Yu Liu, Rui Liu, Jia-Qi Li, Fang Huang, Jiang-Bo Wan, Si-Guo Hao","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.024","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.024","url":null,"abstract":"<p><strong>Objective: </strong>To explore a predictive model that can better predict the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), and validate its clinical value.</p><p><strong>Methods: </strong>Clinical data of 134 newly treated DLBCL patients were collected from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2015 to January 2020. Several risk factors of the patients were screened and analyzed, a novel prognostic model were then established based on this, and its clinical application potential was validated.</p><p><strong>Results: </strong>In the novel model, predicting progression-free survival (PFS) based on the age at initial treatment, albumin level, Hans classification, Ann Arbor stage, and BCL2 expression showed better predictive performance than International Prognostic Index (IPI) score (AUC: 0.788 <i>vs</i> 0.620，<i>P</i> <0.001). Predicting overall survival (OS) based on the age at initial treatment, albumin level, lactate dehydrogenase (LDH) level, and expressions of BCL2 and MUM1 proteins also showed better predictive performance for mortality risk than IPI score (AUC: 0.817 <i>vs</i> 0.624，<i>P</i> <0.001).</p><p><strong>Conclusion: </strong>This novel prognostic model can better predict the survival prognosis of DLBCL patients compared to the IPI scoring system.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"789-795"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression of Interleukin-10 and Interleukin-15 in Patients with Multiple Myeloma and Its Clinical Significance].","authors":"Xiao-Dong Zhang, Meng Li, Hai-Xia Liu, Dan-Feng Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.030","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.030","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression and clinical significance of interleukin-10 (IL-10) and interleukin-15 (IL-15) in patients with multiple myeloma (MM).</p><p><strong>Methods: </strong>Eighty newly diagnosed MM patients in Department of Hematology in Nanyang First People's Hospital from September 2020 to January 2023 were selected as observation group, and 80 healthy people in our hospital were selected as control group. The expression of IL-10 and IL-15 of the two groups were detected, and survival analysis was conducted for the MM patients.</p><p><strong>Results: </strong>The levels of IL-10 and IL-15 in the observation group before treatment were significantly higher than those in the control group (both <i>P</i> <0.05). The levels of IL-10 and IL-15 in different DS stage had significant differences in MM patients (both <i>P</i> <0.05). The levels of IL-10 and IL-15 in stage II and stage III had no significant differences, which were both significantly higher than those in stage I (both <i>P</i> <0.05). The levels of IL-10 and IL-15 in sCR+CR group after treatment were significantly lower than those before treatment (both <i>P</i> <0.05). The levels of IL-10 and IL-15 in VGPR+PR group after treatment were also significantly lower than those before treatment (both <i>P</i> <0.05), but higher than those in the sCR+CR group (both <i>P</i> <0.05). The progression-free survival (PFS) and overall survival (OS) of patients with IL-10>22.01 pg/ml were significantly shorter than those with IL-10≤22.01 pg/ml (both <i>P</i> <0.001). The PFS and OS of patients with IL-15>48.56 pg/ml were also shorter than those with IL-15≤48.56 pg/ml (both <i>P</i> <0.05).</p><p><strong>Conclusions: </strong>The levels of IL-10 and IL-15 in MM patients are closely related to efficacy and prognosis, and both decreased after treatment. The more reduction, the better effect. Patients with IL-10 and IL-15 below the threshold have longer median PFS and OS.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"828-833"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].","authors":"Guo-Rong Wang, Guang-Zhong Yang, Yun Leng, Yin Wu, Ai-Jun Liu, Wen-Ming Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.021","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.021","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To analyze the effect of COVID-19 infection on the mobilization and collection of autologous peripheral blood stem cells in patients with multiple myeloma.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The general baseline data, treatment factors before mobilization collection, collection status, and treatment overview after collection of autologous peripheral blood stem cells at Beijing Chaoyang Hospital affiliated with Capital Medical University from January 1, 2020 to July 15, 2023 were analyzed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;269 patients underwent mobilization and collection of autologous peripheral blood stem cells. Among them, 32 cases with COVID-19 infection history (COVID-19 group) and 237 cases without COVID-19 infection history (non-COVID-19 group). In the COVID-19 group, 17 cases were treated with chemotherapy (etoposide)+G-CSF, and 15 cases were treated with plerixafor +G-CSF. In the non-COVID-19 group, 214 cases were treated with chemotherapy +G-CSF, 17 cases were treated with plerixafor +G-CSF, and 6 cases were treated with chemotherapy + plerixafor +G-CSF. The number of CD34&lt;sup&gt;+&lt;/sup&gt; cells, collection success rate, and excellence rate in the COVID-19 group and the non-COVID-19 group were ［5.52 (0.94-26.87) &lt;i&gt;vs&lt;/i&gt; 4.80 (0.53-37.20)］×10&lt;sup&gt;6&lt;/sup&gt;/kg (&lt;i&gt;P&lt;/i&gt; =0.610), (93.8% &lt;i&gt;vs&lt;/i&gt; 85.2%) (&lt;i&gt;P&lt;/i&gt; =0.275), (62.5% &lt;i&gt;vs&lt;/i&gt; 49.4%) (&lt;i&gt;P&lt;/i&gt; =0.190), respectively. Among 113 patients mobilized with etoposide +G-CSF, the number of CD34&lt;sup&gt;+&lt;/sup&gt; cells, success rate, and excellence rate collected from COVID-19 infection (17 cases) and non-COVID-19 infection (96 cases) were ［7.54 (2.66-26.87) &lt;i&gt;vs&lt;/i&gt; 7.78 (2.26-37.20)］×10&lt;sup&gt;6&lt;/sup&gt;/kg (&lt;i&gt;P&lt;/i&gt; =0.847), (100.0% &lt;i&gt;vs&lt;/i&gt; 100.0%) (no &lt;i&gt;P&lt;/i&gt; value), (82.4% &lt;i&gt;vs&lt;/i&gt; 86.5%) (&lt;i&gt;P&lt;/i&gt; =0.655), respectively. Among 32 patients mobilized by plerixafor +G-CSF, the number of CD34&lt;sup&gt;+&lt;/sup&gt; cells, success rate and excellence rate of COVID-19 infection (15 cases) and non-COVID-19 infection (17 cases) were ［3.82 (0.94-7.27) &lt;i&gt;vs&lt;/i&gt; 4.11 (0.53-9.05)］×10&lt;sup&gt;6&lt;/sup&gt;/kg (&lt;i&gt;P&lt;/i&gt; =0.821), (86.7% &lt;i&gt;vs&lt;/i&gt; 88.2%) (&lt;i&gt;P&lt;/i&gt; =0.893), (40.0% &lt;i&gt;vs&lt;/i&gt; 35.3%) (&lt;i&gt;P&lt;/i&gt; =0.784), respectively. In 32 patients with COVID-19 infection, the number of CD34&lt;sup&gt;+&lt;/sup&gt; cells collected by etoposide +G-CSF (17 cases) and plerixafor +G-CSF (15 cases), as well as the success rate and excellence rate were ［7.54 (2.66-26.87) &lt;i&gt;vs&lt;/i&gt; 3.82(0.94-7.27)］×10&lt;sup&gt;6&lt;/sup&gt;/kg (&lt;i&gt;P&lt;/i&gt; =0.004), (100.0% &lt;i&gt;vs&lt;/i&gt; 86.7%) (&lt;i&gt;P&lt;/i&gt; =0.120), (82.4% &lt;i&gt;vs&lt;/i&gt; 40.0%) (&lt;i&gt;P&lt;/i&gt; =0.014), respectively. By 2023.7.31, 232 patients (86.2%, 232/269) had received transplantation, including 24 patients in the COVID-19 group and 208 patients in the non-COVID-19 group. The median number of CD34&lt;sup&gt;+&lt;/sup&gt; cells infused in the two groups was ［3.67 (2.50-13.44) &lt;i&gt;vs&lt;/i&gt; 3.11(1.12-19.89)］×10&lt;sup&gt;6&lt;/sup&gt;/kg (&lt;i&gt;P&lt;/i&gt; =0.058), the median days of neutrophil engraftment ［11(9-13) &lt;i&gt;vs&lt;/i&gt; 11(9-17)］ (&lt;i&gt;P&lt;/i&gt;","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"455-462"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of the Influencing Factors of ABO Blood Group Antibody Origin and Titer in Neonates].","authors":"Meng-Jiao Yang, Li Zhang, Yu Zhou, Chun Yang, Xiang Shi","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.031","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.031","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the origin and influencing factors the titer of ABO blood group antibody in neonates.</p><p><strong>Methods: </strong>A total of 303 newborn blood samples collected in our hospital from August 2023 to March 2024 were selected for the detection of ABO blood group settings and the determination of the total titers of IgG and IgM blood group antibodies in plasma. IgM antibodies were treated with dithithreitol (DTT) to determine the titers of IgG antibodies. The total titer of the blood group antibody was compared with that of the IgG antibody. The clinical data of mothers and newborns were collected, and the correlation between the antibody titer and these clinical data was analyzed.</p><p><strong>Results: </strong>Among the 303 newborn specimens, 14 cases (4.62%) were identified to possess blood group antibodies. The influence of the maternal ABO blood group on the generation of high-potency blood group antibodies in newborns was observed to follow the order of O>B>A>AB, with a significant statistical difference ( <i>P</i> < 0.01). Of the 123 (40.59%) newborns born to mothers of type O, 121 (98.37%) had blood group antibody titers > 2. Of the 20 (6.60%) newborns born to mothers of type AB, all 20 (100.00%) had blood group antibody titers < 2. Among 89 (29.37%) mothers of type A and 71 (23.43%) mothers of type B, the titer of 100% newborn blood group antibody was less than 2, when the newborn blood group was incompatible with the mother's blood group; the titer of the newborn blood type antibody was higher or lower, when the newborn blood type was compatible with the mother's blood type. The titer of the newborn blood group antibodies is related to the number of pregnancies of the mothers and has no association with other clinical data (such as the mother's number of obortions), the number of production, fetal gestation age.</p><p><strong>Conclusion: </strong>The majority of ABO blood group antibodies in neonates are IgG antibodies from the mothers, and few are produced by the neonates themselves. In some neonates, IgG anti-A and/or anti-B can agglutinate with anti-stereotyped cells at room temperature. The maternal ABO blood type is the primary factor influencing the titer of the newborn blood type. The number of maternal pregnancies is a factor affecting the high titer ABO blood group antibodies in newborns.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"520-525"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Mechanism of Iron in Lymphocyte and Plasma Cell Diseases--Review].","authors":"Shu-Lin Luo, Fei-Fei Yang, Yan-Li Xu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.044","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.044","url":null,"abstract":"<p><p>As an important trace element, iron is involved in a variety of physiological processes. In recent years, studies have found that the occurrence and development of tumors are closely related to abnormal iron metabolism, and the mode of action is obviously heterogeneous. Tumor cells need more iron to promote their survival and proliferation, but iron overload can also have adverse effects on tumor cells, such as ferroptosis. Ferroptosis is a special regulatory mechanism of cell death, which is different from other regulated cell death pathways. It mainly induces cell death through excessive accumulation of iron-dependent lipid peroxide and reactive oxygen species (ROS). Recent studies have found that in the blood system, tumor cells of lymphoma and multiple myeloma (MM) are more sensitive to ferroptosis and affect disease progression through a variety of mechanisms. In this review, the mechanisms of ferroptosis in some subtypes of lymphoma and MM are described in detail, and the correlation between ferroptosis of hematological tumor cells and the occurrence and development of hematological tumors is revealed, aiming to provide new ideas for the treatment of these hematological diseases.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"601-605"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Significance of XPO1 High Expression in Diffuse Large B-Cell Lymphoma and Its Mechanism].","authors":"Jing Zhang, Yan Gu, Jia-Heng Guan, Xue Wu, Bao-An Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.013","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.013","url":null,"abstract":"<p><strong>Objective: </strong>To explore the expression and clinical significance of XPO1 in newly diagnosed adult diffuse large B-cell lymphoma (DLBCL), and further investigate its functional mechanism.</p><p><strong>Methods: </strong>Immunohistochemical testing was conducted for XPO1 expression in 93 cases of DLBCL and 30 cases of reactive lymphoid hyperplasia. A risk model was construed to find survival related genes in DLBCL patients. Cell proliferation, apoptosis, and cell cycle assays were performed to explore the effect of XPO1 inhibitor (KPT-8602) and <i>XPO1</i> knockdown. Differential expression gene (DEG) was examined based on the transcriptomes.</p><p><strong>Results: </strong>The expression of XPO1 in DLBCL patients was higher than that of the controls. Compared with XPO1 low-expression group, XPO1 high-expression group had a worse prognosis. The constructed risk model indicated that <i>XPO1</i> and 14 genes in nucleocytoplasmic transport pathway (NTP) might be potential prediction marker of adverse outcome in DLBCL. Moreover, KPT-8602 as well as the <i>XPO1</i> knockdown could inhibit cell proliferation, promote apoptosis, and induce cell cycle arrest in two DLBCL cell lines, Farage and SU-DHL-4. Based on the gene expression profiling in the datasets of DLBCL, patients were classified into <i>XPO1</i> high and <i>XPO1</i> low expression groups, and the <i>MYBL1</i> was identified as the down-stream effector of <i>XPO1</i>. Inhibiting the function of XPO1 or reducing its expression can significantly decrease the expression of <i>MYBL1</i> Conclusion: XPO1 is highly expressed in DLBCL, which is associated with poor prognosis. The oncogenic roles of the new <i>XPO1/MYBL1</i> signaling are identified in DLBCL and XPO1 inhibitor may be a potential option for newly-diagnosed DLBCL patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"393-406"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Effects of Pomalidomide-Based Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma].","authors":"Man Yang, Yan Huang, Ling-Xiu Zhang, Guo-Qing Lyu, Lu-Yao Zhu, Xian-Kai Liu, Yan Guo","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.017","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.017","url":null,"abstract":"<p><strong>Objective: </strong>To study the clinical effects of pomalidomide-based regimen in the treatment of relapsed and refractory multiple myeloma (RRMM).</p><p><strong>Methods: </strong>60 patients with RRMM in hematology department of the First Affiliated Hospital of Xinxiang Medical University from November 2020 to January 2023 were selected. Among them, 15 cases were treated with PDD regimen (pomalidomide + daratumumab + dexamethasone), and 45 cases were treated with PCD regimen (pomalidomide + cyclophosphamide + dexamethasone). The clinical effects were evaluated.</p><p><strong>Results: </strong>The median number of treatment cycles for the entire cohort was 5 (2-11), with an overall response rate (ORR) of 75.0%. The ORR of patients treated with PDD regimen was 73.3%, while the ORR of patients treated with PCD regimen was 75.6%. The ORR of 46 patients with non high-risk cytogenetic abnormalities (non-HRCA) was 86.9%, significantly higher than the 35.7% of 14 patients with HRCA (χ² =15.031, <i>P</i> < 0.05). The median PFS for all patients was 8.0(95%<i>CI</i> : 6.8-9.1) months and the median OS was 14.0 (95%<i>CI</i> : 11.3-16.7) months. Among patients treated with PDD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 7.0(95%<i>CI</i> : 4.6-9.3) months <i>vs</i> 4.0(95%<i>CI</i> : 3.1-4.8) months, χ² =5.120, <i>P</i> < 0.05; OS: not reached <i>vs</i> 6.0(95%<i>CI</i> : 1.1-10.9) months, χ² =9.870, <i>P</i> < 0.05]. Among patients treated with PCD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 9.0(95%<i>CI</i> : 6.2-11.8) months <i>vs</i> 6.0(95%<i>CI</i> : 5.4-6.6) months, χ²=14.396, <i>P</i> < 0.05; OS: not reached <i>vs</i> 11.0(95%<i>CI</i> : 6.4-15.6) months, χ² =7.471, <i>P</i> < 0.05].</p><p><strong>Conclusion: </strong>The pomalidomide-based regimen has a good clinical effect and safety in the treatment of RRMM.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"431-436"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression and Function of miR-144 in β-Thalassemia].","authors":"Lan Yang, Ling Ling, Fan Yang, Lei Yang, Zhi-Chen Dai, Duo-Nan Yu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.027","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.027","url":null,"abstract":"<p><strong>Objective: </strong>To explore the expression and function of microRNA-144 (miR-144) in β-thalassemia (β-thal).</p><p><strong>Methods: </strong>The expression of miR-144 during the differentiation of murine erythroleukemia (MEL) cells and mouse embryonic liver-derived erythroid precursor cells was analyzed by real-time fluorescence quantitative PCR (qRT-PCR); The expression levels of miR-144 in peripheral blood and day-14.5 embryonic hepatocytes of wild-type (WT) and β-thal mice, as well as the expression levels of miR-144 in peripheral blood of β-thal patients, was also measured by qRT-PCR. The proportion of Ter119 and CD71 double positive cells in peripheral blood of mild and severe β-thal mice was analyzed by flow cytometry, and the expression levels of miR-144 in the peripheral blood of mild and severe β-thal mice and patients were compared; Bone marrow nucleated erythrocytes from WT mice and β-thal mice were sorted and the expression levels of miR-144 potential target genes were analyzed by gene chip.</p><p><strong>Results: </strong>The expression levels of miR-144 were gradually increased during the directed differentiation of mouse MEL cells and embryonic hepatocytes to the erythroid lineage (<i>r</i> _MEL=0.97, <i>r</i> _{embryonic hepatocytes}=0.86); Compared with WT mice, the expression levels of miR-144 in peripheral blood and 14.5-day embryonic hepatocytes of β-thal mice were significantly increased (<i>P</i> < 0.05); Compared with healthy controls, the patients with β-thal showed an increased expression levels of miR-144 in peripheral blood (<i>P</i> < 0.05). Compared with mice and humans with mild β-thal, the expression levels of miR-144 in peripheral blood of those with severe β-thal were significantly increased (<i>P</i> < 0.05). The expressions of potential target genes of miR-144 in nucleated erythroid cells of the β-thal mice were significantly reduced compared to the WT group.</p><p><strong>Conclusion: </strong>The expression level of miR-144 gradually increases in erythroid development, and compared with mild β-thal patients, the expression level of miR-144 in the peripheral blood is higher in severe β-thal patients. MiR-144 is expected to be an auxiliary diagnostic indicator for β-thal in clinical practice.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"491-497"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}